Another way to increase the NKG2D mediated anti-tumor effect of γδ T cells, is to use recombinant immunoligands consisting of a CD20 single-chain fragment variable (scFv) linked to MICA or ULBP2. This evidence concerns the gene KLRK1 and neoplasm.